Jacobio Pharmaceuticals Group Co., Ltd.
1167.HK · HKSE
Market closed4.65-0.570000 (-10.92%)
Key statistics
Previous close5.22
Open5.17
Day high5.19
Day low4.61
52-week high11.80
52-week low3.98
Market cap3.64B
Volume4.19M
Average volume3.08M
P/E ratio-44.69
Forward P/E—
EPS-0.10
Dividend yield0.00%
Market context
Why it moved
1167.HK experienced a sharp decline likely driven by a broader market selloff in Hong Kong equities, compounded by sector-specific selling pressure and heightened investor risk aversion amid concerns over AI-related valuations and rising bond yields.
What is happening
Recent company-specific developments and publisher coverage.
www.marketscreener.com · June 9, 2026Jacobio Pharmaceuticals Group Co., Ltd. commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026.TradingView · June 8, 2026Jacobio Pharmaceuticals To Repurchase Up To 78.37 Million Shares, 10% Of Issued SharesCaixin Global · March 12, 2026$100 Million AstraZeneca Deal Puts Chinese Biotech Jacobio on Path to ProfitChina Daily · December 25, 2025Jacobio, AstraZeneca ink cancer drug dealBloomberg.com · December 22, 2025Watch Jacobio Strikes New Cancer Drug Deal with AstraZenecaClinical Trials Arena · December 1, 2025Jacobio’s NSCLC combo touts 71% ORR in Phase I/IIa trial Mt Newswire · June 8, 2026Jacobio Pharmaceuticals Launches HK$100 Million Share Buyback Mt Newswire · May 19, 2026Jacobio Pharmaceuticals Says Cash Runway Extends at Least Four Years Mt Newswire · March 11, 2026Jacobio Pharmaceuticals' 2025 Loss Narrows Mt Newswire · December 22, 2025Jacobio Pharmaceuticals Sells JAB-23E73 License to AstraZeneca Mt Newswire · December 3, 2025Jacobio Pharmaceuticals Unit Receives Upfront Payment From Oceanpine Capital; Shares Lose 3% Mt Newswire · November 13, 2025Jacobio Pharmaceuticals Appoints Co-CEO Mt Newswire · October 16, 2025Jacobio Pharmaceuticals Unit to Sell 80% Stake in Jacoray to Oceanpine Capital